Dr. Harald Paganetti is the Director of Physics Research at the Department of Radiation Oncology at Massachusetts General Hospital and a Professor of Radiation Oncology at Harvard Medical School. He received his PhD in experimental nuclear physics in 1992 from the University of Bonn, Germany, and has been working in radiation therapy research on experimental as well as theoretical projects since 1994. He has authored and co-authored close to 300 peer-reviewed publications with an h-index of 80. He is renowned particularly for his work on proton therapy and has edited three books on Proton Therapy. His main interests are computer simulations and bio-mathematical modeling of physical and biological properties of radiation fields. Dr. Paganetti has been awarded numerous research grants from the National Cancer Institute. He serves on the executive editorial board of 'Physics in Medicine and Biology' and is a member of the National Council on Radiation Protection and Measurements (NCRP). Furthermore, he serves on various task groups and committees for associations such as the American Association of Physicists in Medicine (AAPM) and the American Society for Radiation Oncology (ASTRO). For example, he has been the Physics Track Chair for the annual ASTRO meeting from 2015-2018 and the Program Director for the annual AAPM meeting 2011-2012. In 2013 he was awarded the 'A. Clifford Barger Excellence in Mentoring Award' by the Harvard Medical School for his efforts in mentoring junior researchers.

SK Patch earned degrees in applied mathematics (Stanford BS '89, UC Berkeley PhD '94) and won post-doctoral fellowships from the National Science and Av Humboldt Foundations. She joined General Electric's research center to develop reconstruction algorithms for cone-beam CT. GE transitioned to a cone-beam back projector and Dr Patch transitioned to algorithm development for thermoacoustic tomography. Upon returning to academia, Dr Patch became more applied, and developed a low frequency thermoacoustic system for imaging tissue samples ex vivo. In 2011, Dr Patch was introduced to the problem of range verification during particle therapy, and gradually shifted research focus from imaging to therapy. Acoustic Range Estimates was organized in 2018 and won SBIR funding from NIH in 2019 and 2022.

John P. Perentesis, MD, FAAP, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. His laboratory is also using tumor patients genomics research for personalizing therapies. In national efforts for new anticancer drug development, he serves in key roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest children's cancer research entity. In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national COG Executive Committee. He also serves as vice-chair for the COG Adolescent & Young Adult Cancer Steering Committee and as a member of the Hematology/Oncology and Institutional Performance Monitoring Steering Committees. Dr. Perentesis has been elected by his peers for inclusion in the Best Doctors in America List since 1998.

• Researcher and Medical Physicist from Helsingborg, Sweden. • M.Sc. (2009) and Ph.D. (2014) in Medical Radiation Physics, Lund University, Sweden. • 2014-2017, Post-doc on FLASH Radiation, Lausanne, Switzerland • From 2017, Clinical Medical Physicist, Group leader on FLASH Radiotherapy, Skåne University Hospital, Sweden • From October 2019, MRC Investigator, Group leader – Biology and Physics of FLASH Radiation, MRC Oxford Institute for Radiation Oncology, University of Oxford, UK My research ambitions are to further improve our knowledge in the field of Medical Radiation Physics and Radiobiology. My goal is to improve on current clinical practice in radiotherapy, to achieve a more efficient patient treatment and with less adverse effect for the patients. With that goal in mind, the last eight years I have focused my research on FLASH radiation, i.e. radiation delivered at ultra-high dose rates. Currently, I am heading one of the most prominent teams in this field of radiation research, at the University of Oxford. FLASH radiation is a novel radiotherapy technique that show great potential in improving cancer treatment. However, very little is known about the biological mechanisms behind the highly beneficial FLASH effect. My research team aims to identify these mechanisms, explain the effect, and to find the optimal way of implementing the technique in clinical practice.

Timmy is a graduate student in the Department of Bioengineering at the University of Washington, Seattle. As a research assistant in the Neural Systems Lab, Timmy applies machine learning and data-driven approaches to challenges in biology and engineering. Currently, Timmy is employed as a research intern in the Flash Program at Varian, a Siemens Healthineers Company.

Brian W. Pogue, PhD is the Chair of the Department of Medical Physics at the University of Wisconsin Madison, and Professor of Medical Physics, Radiology and Human Oncology, and is Adjunct Professor of Engineering Science at Dartmouth and maintains an active research laboratory in both locations. This work has led to US Patents, with 12 issued and 29 pending, and more than 450 peer-reviewed papers. Dr Pogue is a Fellow member of Optica, SPIE, AIMBE, and the National Academy of Inventors, and is the Editor-in-Chief of the Journal of Biomedical Optics, the oldest and highest impact journal dedicated to the field of biomedical optics and biophotonics. Dr Pogue’s research is at the intersection of medical physics and biomedical engineering, where the invention of new tools can have impact on cancer imaging and therapy. The particular focus is in the design and engineering of optical devices that are used to image or characterize disease or guide decisions in disease treatment. His research group was the first in the world to invent a unique system for imaging radiation dose with Cherenkov light emission. His research group also works on the concept of molecular guided surgery, allowing surgeons to visualize the molecular features of tissue to help them guide resection.

Philip Poortmans is associated at the Iridium Netwerk and University of Antwerp. He is former President of the European Society for Radiotherapy and Oncology and of the European Cancer Organization. By the way, he is honorary member of, among others, The European Society for Surgical Oncology.